MedTrace Logo

Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC

NCT01282437 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 315

Last updated 2015-04-10

No results posted yet for this study

Summary

For patients with stage III non-small cell lung cancer, which is radically treated, we will investigate whether prophylactic cranial irradiation (PCI) should become standard of care to prevent brain metastases.

Conditions

  • Non Small Cell Lung Cancer (NSCLC)
  • Radical Treatment
  • Stage III Non-Small Cell Lung Cancer

Interventions

RADIATION

Prophylactic Cranial Irradiation

* 18 fractions of 2Gy * 12 fractions of 2.5Gy * 10 fractions of 3 Gy

Sponsors & Collaborators

  • University Medical Center Groningen

    collaborator OTHER

  • The Netherlands Cancer Institute

    collaborator OTHER

  • Maastricht Radiation Oncology

    lead OTHER

Principal Investigators

  • Dirk De Ruysscher, MD, PhD · NVALT oncology foundation

  • Harry Groen, MD, PhD · University Medical Center Groningen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2014-09-30
Completion
2015-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01282437 on ClinicalTrials.gov